Chongqing pharma and distribution group known for its Huoxiang Zhengqi traditional digestive-remedy liquid.
Chongqing pharma and distribution group known for its Huoxiang Zhengqi traditional digestive-remedy liquid.
Pharmaceutical distribution adds large sales volume at thin margins, while the branded remedy and other over-the-counter products sold through pharmacies carry most of the profit. The distribution arm supplies drugs and medical products to hospitals and pharmacies in the Chongqing region.
In one line: A Chinese TCM OTC and distribution conglomerate.
Moat: narrow (brand, distribution). Long-established OTC brand plus a regional pharma distribution network.
Headquarters: Chongqing, China · Employees: 10,864
Size Chongqing Taiji Industry (Group) (600129.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $982M, the 2187th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.97 on 18 Nov 2026.
Performance Over six months the shares fell 19.8%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue fell 4.5% over the last twelve months (peer median +9.8%); the operating margin is 1.5% (peer median 12.6%).
Valuation It trades at 69.8× forward earnings against a peer median of 19.8× (most expensive of 14).
Capital Return on invested capital runs 1.0 points below its cost of capital (5.2% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥9.59B | CN¥10.4B | CN¥12.3B | CN¥15.4B | CN¥14.0B |
| Revenue growth | — | -15% | -20% | +10% | — |
| Gross profit | CN¥3.03B | CN¥2.76B | CN¥4.64B | CN¥7.14B | CN¥6.00B |
| EBITDA | n/a | CN¥812M | CN¥889M | CN¥1.62B | CN¥1.15B |
| Net income | -CN¥19.6M | CN¥121M | CN¥26.7M | CN¥822M | CN¥354M |
| Free cash flow | -CN¥215M | CN¥64.1M | -CN¥1.46B | -CN¥160M | CN¥1.26B |
| Capital expenditure | CN¥400M | CN¥523M | CN¥832M | CN¥836M | CN¥532M |
| Total debt | CN¥6.07B | CN¥6.44B | CN¥5.62B | CN¥4.86B | CN¥5.02B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Chongqing Taiji Industry (Group) 600129.SS | $982M | -20% | -4% | 2% | 69.8× | n/a |
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600129.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.4% | -6.5% | 6th lowest of 21 |
| 6-month return | -19.8% | -10.6% | 8th lowest of 21 |
| Distance from 52-week high | -42.8% | -33.9% | 9th lowest of 21 |
| Revenue growth (TTM) | -4.5% | +9.8% | 6th lowest of 19 |
| Operating margin | 1.5% | 12.6% | 4th lowest of 19 |
| Forward P/E | 69.8× | 19.8× | most expensive of 14 |
| ROIC minus cost of capital | -1.0 pp | -0.4 pp | 9th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 12.5× | 2.3% | -0.5% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 15.9× | 17.6% | +7.8% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 42.3× | 11.6% | +4.9% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | n/a | 7.7% | -6.9% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | n/a | n/a | n/a |